Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
← catalyst calendarNCT05102721 · readout in 864 d
Sponsored by Vaccinex Inc. (industry) · VCNX — their whole pipeline →. With University of Rochester.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
48estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-10 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Pancreatic Adenocarcinoma
Intervention
- Drug: Avelumab and Pepinemab
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured 10 years
Permalink · VCNX's whole pipeline · Catalyst calendar · Every registered study · What changed